Cyrus J. Lawrence’s Regeneron Pharmaceuticals REGN Stock Holding History

Cyrus J. Lawrence’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,293	Closed	-$1.63M	–	140
2024 Q4	$1.63M	Sell	2,293 -15	-0.6%	-$12.6K	0.32%	40
2024 Q3	$2.43M	Hold	2,308	–	–	0.48%	39
2024 Q2	$2.42M	Hold	2,308	–	–	0.49%	41
2024 Q1	$2.22M	Buy	+2,308	New	+$2.19M	0.49%	41
2023 Q3	$1.9M	Hold	2,308	–	–	0.52%	41
2023 Q2	$1.66M	Hold	2,308	–	–	0.36%	41
2023 Q1	$1.9M	Hold	2,308	–	–	0.55%	40
2022 Q4	$1.67M	Hold	2,308	–	–	0.5%	40
2022 Q3	$1.59M	Hold	2,308	–	–	0.31%	42
2022 Q2	$1.36M	Buy	2,308 +3	+0.1%	+$1.95K	0.39%	43
2022 Q1	$1.61M	Buy	+2,305	New	+$1.46M	0.37%	44

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cyrus J. Lawrence's REGN Position: Q1 2025 in Review

Cyrus J. Lawrence sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 2,293 shares — an estimated $1.63M sold.

Cyrus J. Lawrence first reported a position in REGN in Q1 2022 and held it in 11 quarters. The position peaked at $2.43M in Q3 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Cyrus J. Lawrence reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Cyrus J. Lawrence sold 2,293 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $1.63M.
Cyrus J. Lawrence first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 11 quarters.
Cyrus J. Lawrence's Regeneron Pharmaceuticals position peaked at $2.43M in Q3 2024.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Cyrus J. Lawrence's 13F filing for Q1 2025, filed 15 May 2025.